Crohn's Disease: How HUMIRA Works
You need adobe flash player to watch this video.
In Crohn's disease, excess TNF attacks the intestines
Many patients with Crohn's disease produce too much of a protein called TNF (tumor
necrosis factor) in their body. This excess TNF attacks the intestines and other
parts of the gastrointestinal (GI) tract, and can
cause them to become inflamed. This can result in the pain, diarrhea, and other
symptoms of Crohn's disease.
HUMIRA targets TNF to fight Crohn's disease
HUMIRA belongs to a class of biologics known as TNF blockers. TNF blockers have
a specific target in the body and work by binding the excess TNF to help reduce the
inflammation that can lead to Crohn's symptoms.
HUMIRA is a prescription medicine used to reduce signs and symptoms, and to achieve and
maintain clinical remission in adults with moderate to severe Crohn's disease who have not
responded well to conventional treatments, and in these adults who have also lost response
to or are unable to tolerate infliximab.
HUMIRA has been shown to be effective
In two clinical studies, more than half of the patients who took HUMIRA had significant
symptom relief, versus about 1 out of 3 who took placebo. In the same studies, 36% and 21% of patients
who took HUMIRA achieved remission, versus 12% and 7% who took placebo. Results were at four weeks.
HUMIRA is not right for everyone. While HUMIRA can block the action of TNF,
it also can affect how your immune system normally works and may cause serious side